Credit Suisse Ag Kinnate Biopharma Inc. Transaction History

Credit Suisse Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$5.26 - $12.19 $862 - $1,999	-164 Reduced 99.39%	1 $0
Q3 2022 Nov 10, 2022	BUY	$9.86 - $15.76 $1,350 - $2,159	137 Added 489.29%	165 $2,000
Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $208 - $364	28 New	28 $0

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.